TEVA-MEDROXYPROGESTERONE
As listed in the register: TEVA-MEDROXYPROGESTERONE
2.5 mg · tablet
- Prescription only
- Urinary and reproductive system, hormones
- Active substance
- Medroxyprogesterone Acetate
- Made by
- Teva Canada Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Medroxyprogesterone). It describes the substance, not this exact product.
Medroxyprogesterone acetate (MPA) administered orally or parenterally in the recommended doses to women with adequate endogenous estrogen, transforms proliferative into secretory endometrium.
Androgenic and anabolic effects have been noted, but the drug is apparently devoid of significant estrogenic activity.
Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine.
Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates.
Administration of medroxyprogesterone acetate with food increases the bioavailability of MPA.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2022-10-09
Safety of the active substance
From the US prescribing label for the same active substance (Medroxyprogesterone). It describes the substance, not this exact product.
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia.
- Medroxyprogesterone acetate is contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding.
- Known, suspected, or history of breast cancer.
- Known or suspected estrogen- or progesterone-dependent neoplasia.
- Active DVT, PE, or a history of these conditions Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States8 matching products
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Teva Canada Limited |
|---|---|
| Active substance | Medroxyprogesterone Acetate |
| Used in | Urinary and reproductive system, hormones |
| Strength | 2.5 mg |
| Form | tablet |
| Classification | G03DA02 · Urinary and reproductive system, hormones |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02221284 |
| DPD drug code | 43299 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
3 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.